Tumor hypoxia adversely affects clinical radiation response of head and neck squamous cell carcinoma. 18F-fluoromisonidazole positron emission tomography ([F-18]FMISO-PET) offers a noninvasive means of assessing viable hypoxic tissue in tumor. We evaluate hypoxia imaging with [F-18]FMISO-PET in HNSCC treated with chemoradiotherapy. A total of 11 patients with HNSCC agreed to participate in this study. All of the patients underwent pretreatment [F-18]FMISO-PET. SUVmax and tumor-to-muscle ratios(TMR) were measured as hypoxia indicators. 9 patients of them had primary tumor hypoxia. 2 of 10 patients with neck metastasis had nodal hypoxia. All patients were treated with chemoradiation therapy. As clinical response of chemoradiotherapy, 8 patients achieved CR, 3 patients achieved PR. Remain viable carcinoma cell of 3 PR cases existed in hypoxia region imaged with [F-18]FMISO-PET. The current result suggest that we could apply 18-F fluoromisonidazole positron emission tomography/computed tomography ([F-18]FMISO-PET/CT)-guided intensity-modulated radiotherapy(IMRT) in dose escalation to attack the hypoxic volume of a tumor mass without increasing the normal tissue dose in head and neck cancer patients in order to improve the clinical response.
![](https://freepngimg.com/download/social_media/63059-media-icons-telegram-twitter-blog-computer-social.png)
Stay updated, free dental videos. Join our Telegram channel
![](https://videdental.com/wp-content/uploads/2020/02/logo-gold.png)
VIDEdental - Online dental courses
![](https://videdental.com/wp-content/uploads/2023/09/appstore.png)
![](https://videdental.com/wp-content/uploads/2023/09/google-play.png)